Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro) — Medicare Part D spending
Eli Lilly & Co. · Rank #210 by total Part D spend · CMS data year 2023
Medicare Part D spent $213,875,690 on Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro) in 2023, the #210 drug by total Part D spending out of 3,598 drugs. That worked out to about $36.40 per dosage unit, $1,249 per claim and $5,277 per beneficiary, across 171,187 claims for 40,527 beneficiaries. Average spending per dosage unit rose +0.5% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro) spending at a glance (2023)
| Metric | Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro) |
|---|---|
| Total Part D spending (2023) | $213,875,690 |
| Total spending (2022) | $226,141,891 |
| Year-over-year change in total spending | -5.4% |
| Average spending per dosage unit (2023) | $36.40 |
| Change in spend per dosage unit (YoY) | +0.5% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +0.7% |
| Average spending per claim (2023) | $1,249 |
| Average spending per beneficiary (2023) | $5,277 |
| Total claims (2023) | 171,187 |
| Beneficiaries (2023) | 40,527 |
| Total dosage units (2023) | 5,875,488 |
| Manufacturer(s) | Eli Lilly & Co. |
| National rank by total spend (of 3,598 drugs) | #210 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $226,141,891 | $213,875,690 | -5.4% |
| Avg spend per dosage unit | $36.22 | $36.40 | +0.5% |
| Avg spend per claim | $1,211 | $1,249 | — |
| Avg spend per beneficiary | $5,315 | $5,277 | — |
| Total claims | 186,762 | 171,187 | — |
| Beneficiaries | 42,546 | 40,527 | — |
How Humalog Mix 75-25 Kwikpen compares with nearby drugs
Drugs with total Part D spending closest to Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro) (this drug, #210) | $213,875,690 | $36.40 | +0.5% |
| Trazodone HCl (#208) | $216,388,379 | $0.21 | +0.6% |
| Latanoprost (#209) | $215,961,787 | $4.26 | -7.4% |
| Imatinib Mesylate (#211) | $211,095,557 | $49.99 | -17.7% |
| Memantine HCl (#212) | $207,922,964 | $0.56 | -14.3% |
| Cosentyx Sensoready Pen (Secukinumab) (#213) | $205,397,019 | $7,222.37 | +9.0% |
Frequently asked questions
How much does Medicare Part D spend on Humalog Mix 75-25 Kwikpen?
Medicare Part D spent $213,875,690 on Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro) in 2023 (the latest CMS data year), across 171,187 claims for 40,527 beneficiaries. That ranks #210 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Humalog Mix 75-25 Kwikpen?
In 2023, the weighted average Medicare Part D spending per dosage unit for Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro) was $36.40. Compared with 2022 it rose +0.5%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Humalog Mix 75-25 Kwikpen?
CMS attributes Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro) to Eli Lilly & Co. in the 2023 Part D spending file. Average spending per claim was $1,249 and per beneficiary $5,277.
Is the Humalog Mix 75-25 Kwikpen figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20